Resveratrol reverses ET-1-evoked mitogenic effects in human coronary arterial cells by activating the kinase-G to inhibit ERK-enzymes

International Journal of Cardiology

Volumn 136, Issue 3, 2009, Pages 263-269

  El Mowafy, A M ^a   Alkhalaf, M ^b   Nassar, N N ^c  

^a MANSOURA UNIVERSITY   (Egypt)

^b KUWAIT UNIVERSITY   (Kuwait)

^c CAIRO UNIVERSITY   (Egypt)

Author keywords

cGMP; Endothein 1; ERK1 2; Human coronary artery; Nitric oxide synthase; Resveratrol

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; CYCLIC GMP DEPENDENT PROTEIN KINASE; ENDOTHELIN 1; GUANYLATE CYCLASE INHIBITOR; KT 5720; KT 5823; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; RESVERATROL; ZAPRINAST;

ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; CORONARY ARTERY; ENZYME ACTIVATION; ENZYME ACTIVE SITE; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; HUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SMOOTH MUSCLE FIBER;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; CARBAZOLES; CELL DIVISION; CELLS, CULTURED; CORONARY VESSELS; CYCLIC GMP-DEPENDENT PROTEIN KINASES; DRUG INTERACTIONS; ENDOTHELIN-1; ENZYME ACTIVATION; ENZYME INHIBITORS; GUANYLATE CYCLASE; HUMANS; MAP KINASE SIGNALING SYSTEM; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; MITOGENS; MUSCLE, SMOOTH, VASCULAR; NITRIC OXIDE SYNTHASE; PROTEIN KINASE INHIBITORS; PYRROLES; STILBENES;

EID: 68049108279     PISSN: 01675273     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijcard.2008.04.094     Document Type: Article

References (35)

1. Schwartz S.M., Campbell G.R., and Campbell J.H. Replication of smooth muscle cells in vascular disease. Circ Res 58 (1986) 427-444
2. Gordon D., Reidy M.A., Benditt E.P., and Schwartz S.M. Cell proliferation in human coronary arteries. Proc Natl Acad Sci U S A 87 (1990) 4600-4604
3. El-Mowafy A.M., and White R.E. Evidence for a tyrosine kinase-dependent activation of the adenylyl cyclase/PKA cascade downstream from the G-protein linked endothelin ET-A receptor in vascular smooth muscle. Biochem Biophys Res Commun 251 (1998) 494-500
4. Gossl M., and Lerman A. Endothelin: beyond a vasoconstrictor. Circulation 1139 (2006) 1156-1158
5. Hoffmann E., Assennato P., Donatelli M., Colletti I., and Valenti T.M. Plasma endothelin-1 levels in patients with angina pectoris and normal coronary angiograms. Am Heart J 135 (1998) 684-688
6. Lin C.L., Winardi W., Jeng A.Y., and Kwan A.L. Endothelin-converting enzyme inhibitors for the treatment of subarachnoid hemorrhage-induced vasospasm. Neurol Res 287 (2006) 721-729
7. Rubanyi G.M., and Polokoff M.A. Endothelins: molecular biology, biochemistry, pharmacology, physiology, and pathophysiology. Pharmacol Rev 46 (1994) 325-415
8. Davis R.J. MAPKs: new JNK expands the group. Trends Biochem Sci 19 (1994) 470-473
9. Knight R.J., and Buxton D.B. Stimulation of c-Jun kinase and mitogen-activated protein kinase by ischemia and reperfusion in the perfused rat heart. Biochem Biophys Res Commun 218 (1996) 83-88
10. De Silva H., Cioffi C., Yin T., Sandhu G., Webb R.L., and Whelan J. Identification of a novel stress activated kinase in kidney and heart. Biochem Biophys Res Commun 250 (1998) 647-652
11. Gille H., Sharrocks A.D., and Shaw P.E. Phosphorylation of transcription factor p62TCF by MAP kinase stimulates ternary complex formation at c-fos promoter. Nature 358 (1992) 414-417
12. Cavigelli M., Dolfi F., Claret F.X., and Karin M. Induction of c-fos expression through JNK-mediated TCF/Elk-1 phosphorylation. EMBO J 14 (1995) 5957-5964
13. Jin N., Siddiqu R.A., English D., and Rhoades R.A. Communication between tyrosine kinase pathway and myosin light chain kinase pathway in smooth muscle. Am J Physiol 271 (1996) H1348-1355
14. Florian JA Watts S.W. Integration of mitogen-activated protein kinase kinase activation in vascular 5-hydroxytryptamine2A receptor signal transduction. J Pharmacol Exp Ther 284 (1998) 346-355
15. Kopp P. Resveratrol, a phytoestrogen found in red wine. A possible explanation for the conundrum of the 'French paradox'?. Eur J Endocrinol 1386 (1998) 619-620
16. Jang M., Cai L., Udeani G.O., et al. Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science 2755297 (1997) 218-220
17. Kar P., Laight D., Shaw K.M., and Cummings M.H. Flavonoid-rich grapeseed extracts: a new approach in high cardiovascular risk patients?. Int J Clin Pract 6011 (2006) 1484-1492
18. Fitzpatrick D.F., Hirschfield S.L., and Coffey R.G. Endothelium dependent vasorelaxing activity of wine and other grape products. Am J Physiol 265 (1993) H774-778
19. Chen C.K., and Pace-Asciak C.R. Vasorelaxing activity of resveratrol and quercetin in isolated rat aorta. Gen Pharmacol 272 (1996) 363-366
20. El-Mowafy A.M. Resveratrol activates guanylyl cyclase in coronary arterial smooth muscle: a novel signaling mechanism in support of coronary protection. Biochem Biophys Res Commun 2915 (2002) 1218-1224
21. A- and cyclooxygenase-dependent mechanism. Br J Pharmacol 1183 (1996) 531-536
22. El-Mowafy A.M., and Alkhalaf M. Resveratrol activates adenylyl-cyclase in human breast-cancer cells: a novel, estrogen receptor-independent cytostatic mechanism. Carcinogenesis 245 (2003) 869-873
23. King R.E., Kent K.D., and Bomser J.A. Resveratrol reduces oxidation and proliferation of human retinal pigment epithelial cells via extracellular signal-regulated kinase inhibition. Chem Biol Interact 1512 (2005) 143-149
24. Potter L.R., and Hunter T. Activation of protein kinase-C stimulates the dephosphorylation of natriuretic peptide receptor-B at a single serine residue, a possible mechanism of heterologous desensitization. J Biol Chem 27540 (2000) 31099-31106
25. Griendling K.K., and FitzGerald G.A. Oxidative stress and cardiovascular injury: part II: animal and human studies. Circulation 10817 (2003) 2034-2040
26. Cheng C.M., Hong H.J., Liu J.C., et al. Crucial role of extracellular signal-regulated kinase pathway in reactive oxygen species-mediate endothelin-1 gene expression induced by endothelin-1 in rat cardiac fibroblasts. Mol Pharmacol 63 (2003) 1002-1011
27. Rossi G.P., Sacchetto A., Cesari M., and Pessina A.C. Interactions between endothelin-1 and the renin-angiotensin-aldosterone system. Cardiovasc Res 43 (1999) 300-307
28. Jesmin S., Zaedi S., Shimojo N., et al. Endothelin antagonism normalizes VEGF signaling and cardiac function in STZ-induced diabetic rat hearts. Am J Physiol Endocrinol Metab 2924 (2007) E1030-1040
29. Adlbrecht C., Bonderman D., Plass C., et al. Active endothelin is an important vasoconstrictor in acute coronary thrombi. Thromb Haemost 974 (2007) 642-649
30. Poussier B., Cordova A.C., Becquemin J.P., and Sumpio B.E. Resveratrol inhibits vascular smooth muscle cell proliferation and induces apoptosis. J Vasc Surg 426 (2005) 1190-1198
31. Lucas K.A., Pitari G.M., Kazerounian S., et al. Guanylyl cyclases and signaling by cyclic GMP. Pharmacol Rev 523 (2000) 375-414
32. Soderling S.H., and Beavo J.A. Regulation of cAMP and cGMP signaling, new phosphodiesterases and new functions. Curr Opin Cell Biol 12 (2000) 174-179
33. Zou J., Huang Y., Chen Q., et al. Suppression of mitogenesis and regulation of cell cycle traverse by resveratrol in cultured smooth muscle cells. Intl J Oncol 154 (1999) 647-651
34. Lee J., Kang D.G., Kook H., Kim I.K., and Oh B.K. Differentially-altered vascular guanylate cyclase isoforms in experimental hypertensive rats. J Korean Med Sci 14 (1999) 386-392
35. Arjona A.A., Hsu C.A., Wrenn D.S., and Hill N.S. Effects of natriuretic peptides on vascular smooth-muscle cells derived from different vascular beds. Gen Pharmacol 283 (1997) 387-392